English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16812/19099 (88%)
Visitors : 6058819      Online Users : 35
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/30980


    標題: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
    作者: Leung, Henry W. C.
    Liu, Chung-Feng
    Chan, Agnes L. F.
    貢獻者: China Med Univ, An Nan Hosp, Dept Radiat Therapy
    Min Hwei Coll Hlth Care Management, Dept Nursing
    Chia Nan Univ Pharm & Sci, Dept Informat Management
    China Med Univ, An Nan Hosp, Dept Pharm
    關鍵字: Cost-effectiveness analysis
    ICER
    Advanced hepatocellular carcinoma
    Sorafenib
    日期: 2016-05
    上傳時間: 2018-01-18 11:39:08 (UTC+8)
    出版者: Biomed Central Ltd
    摘要: Objective: Stereotactic body radiotherapy (SBRT) has been shown to improve overall survival in patients with advanced hepatocellular carcinoma. This study aimed to assess the cost-effectiveness of SBRT compared to sorafenib which is the only drug for advanced hepatocellular carcinoma. Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma. Patients transitioned between three health states: stable disease, progression disease and death. We calculated the data on cost from the perspective of our National Health Insurance Bureau. Sensitivity analyses were conducted to determine the impact of several variables. Results: The incremental cost effectiveness ratio (ICER) for sorafenib compared to SBRT was NT$ 3,788,238 per quality-adjusted life year gained (cost/QALY), which was higher than the willingness to pay threshold of Taiwan according to WHO's guideline. One-way sensitivity analysis revealed that the utility of progression disease for the sorafenib treatment, utility of progression free survival for SBRT, utility of progression free survival for sorafenib, utility of PFS to progression disease for SBRT and transition probability of progression disease to dead for SBRT were the most sensitive parameters in all cost scenarios. The Monte-Carlo simulation demonstrated that the probability of cost-effectiveness at a willingness to pay threshold of NT$ 2,213,145 per QALY was 100 % and 0 % chance for SBRT and sorafenib. Conclusion: This study indicated that SBRT for advanced hepatocellular carcinoma is cost-effective at a willingness to pay threshold as defined by WHO guideline in Taiwan.
    關聯: Radiation Oncology, v.11, 69
    Appears in Collections:[資訊管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    30980.pdf1066KbAdobe PDF44View/Open
    index.html0KbHTML137View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback